J&J Covid vaccine adds $502 million in sales to third-quarter
Johnson and Johnson mentioned it offered $502 million of its Covid-19 vaccine inside the third quarter, in its income report Tuesday that beat Wall Street’s income assumptions. Here’s the manner by which J&J did contrasted and what Wall Street expected, as indicated by average estimates compiled by Refinitiv: Changed EPS: $2.60 per share versus $2.35…